Farmas USA

CELG -10% 

jodo

Las ventas de CELG discretas hacen que esté en premarket a -9% . Yo no la llevo pero se que algunos por aquí si. Ahora no tengo ninguna big biotech en portfolio pero como la derriben aún más, me pienso si pescarla

yo tampoco la he leido, pero con ver el premarket a 8,7 me basta para saber que bad news no son.

Ahora a ver que hace en sesion ...

TGTX

el problema con CELG es que va a provocar un gap de apertura hoy en el IBB ... que como no recupere inmediatamente ... pues nos abre la puerta a los 300 para la proxima semana .... y ya tenemos muchas small cap en zonas de soporte importante ...

U.S. District Judge Vince Chhabria has refused to block President Trump's decision to end subsidy payments to health insurers under Obamacare, handing him a victory against Democratic state attorneys general. According to the judge, this kind of emergency order was not necessary, because "most state regulators have devised responses that give millions of lower-income people better health coverage options than they would otherwise have had."

HZNP

Horizon Pharma plc (HZNP) Reports Availability of PROCYSBI (cysteamine bitartrate) in Canada

https://www.streetinsider.com/Corporate+News/Horizon+Pharma+plc+%28HZNP%29+Reports+Availability+of+PROCYSBI+%28cysteamine+bitartrate%29+in+Canada/13426904.html?si_client=intbro

Y sobre la noticia de ayer:

This builds off of the significant results observed in a phase 2 study, alongside breakthrough therapy and fast track designation. This confirmatory trial will enroll 76 patients across 11 centers.

Given the findings published in the New England Journal of Medicine back in May, it would appear as though HZNP has a strong chance at reaching a first approval for this drug. Considering the only effective approaches are palliative or surgical at this time, this is an area of high unmet need, which definitely explains the breakthrough therapy designation from the FDA.

CEMP

Supplemental Disclosure Relating to Proposal 3 (Approval of the Reverse Stock Split)

At the 2017 Annual Meeting, Cempra stockholders will be asked to approve an amendment to Cempra’s certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of Cempra common stock and related matters. Upon the effectiveness of the amendment to Cempra’s certificate of incorporation effecting the reverse stock split, the outstanding shares of Cempra common stock will be reclassified and combined into a lesser number of shares such that one share of Cempra common stock will be issued for a specified number of shares. As disclosed in the definitive proxy statement, such number of shares shall be greater than one and equal to or less than 20, of outstanding Cempra common stock, with the exact number within the range to be determined by Cempra’s board of directors prior to the effective time of such amendment and publicly announced by Cempra.

Cempra’s board of directors has determined that effecting the reverse stock split, at a ratio no greater than 1-for-5, is in the best interests of Cempra and its stockholders. Accordingly, if Proposal 3 is approved, the reverse stock split will become effective immediately prior to the effective time of the merger, with one share of Cempra common stock being issued for no more than five shares of Cempra common stock outstanding as of immediately prior to the effective time of the merger.

Important Note Regarding Reverse Stock Split Proposal

NASDAQ has informed Cempra that, since the merger constitutes a business combination that will result in a “Change of Control” pursuant to Listing Rule 5110(a), Cempra will be required to meet all criteria applicable to a company requesting initial listing on the NASDAQ Global Market. If, at the time of the merger, Cempra does not meet the minimum $4 bid price requirement for initial listings pursuant to NASDAQ Listing Rule 5405(a)(1), Cempra expects that, in accordance with Listing Rule 5110(a), NASDAQ will issue to Cempra a Staff Delisting Determination and begin delisting proceedings pursuant to the Listing Rules 5800 Series. Given that, as of October 25, 2017, the Cempra stock price is trading below the minimum $4 bid price requirement, in order to avoid the potential initiation of delisting proceedings after the closing of the merger (which would be subject to appeal by and, if appealed, would stay the delisting of the Company’s securities pending a hearing with NASDAQ), CEMPRA’S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT CEMPRA STOCKHOLDERS VOTE “FOR” PROPOSAL 3 TO AMEND CEMPRA’S CERTIFICATE OF INCORPORATION TO EFFECT THE REVERSE STOCK SPLIT, AT A RATIO NO GREATER THAN 1-FOR-5.

http://investor.cempra.com/secfiling.cfm?filingid=1193125-17-319518&CIK=1461993

CEMP

Sí, ayer lo leía, el día 3 del 11 si no recuerdo mal, y también que de la nueva empresa tocará el 48%. Hoy supuestamente salen datos trimestrales. Como no han salido ya, deduzco que lo harán al cierre.

Y justo sale un artículo alabándola:

https://www.fool.com/investing/2017/10/26/3-companies-tackling-the-antibiotic-resistant-bact.aspxhttps://www.fool.com/investing/2017/10/26/3-companies-tackling-the-antibiotic-resistant-bact.aspx